Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Pohl

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Annals of the Rheumatic Diseases|July 10, 2012
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensusSusan J Bartlett, Sarah Hewlett, Clifton O Bingham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2011
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trialDouglas S Goodin, Hans-Peter Hartung, Paul O'Connor, et al.
The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.
Clinical Therapeutics|May 1, 2012
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosisJohn P Caloyeras, Bin Zhang, Cheng Wang, et al.
Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2012
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosisIris-Katharina Penner, Brigitte Stemper, Pasquale Calabrese, et al.
Journal of Neurology|August 5, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1bHans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, et al.
Annals of Clinical and Translational Neurology|October 7, 2014
Molecular mechanism underlying the impact of vitamin D on disease activity of MSKassandra L Munger, Karl Köchert, Kelly C Simon, et al.
JAMA Neurology|October 13, 2015
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1bKathryn C Fitzgerald, Kassandra L Munger, Karl Köchert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 12, 2013
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndromeGijsbert J A Nagtegaal, Christoph Pohl, Mike P Wattjes, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Annals of the Rheumatic Diseases|July 10, 2012
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensusSusan J Bartlett, Sarah Hewlett, Clifton O Bingham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2011
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trialDouglas S Goodin, Hans-Peter Hartung, Paul O'Connor, et al.
The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.
Clinical Therapeutics|May 1, 2012
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosisJohn P Caloyeras, Bin Zhang, Cheng Wang, et al.
Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2012
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosisIris-Katharina Penner, Brigitte Stemper, Pasquale Calabrese, et al.
Journal of Neurology|August 5, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1bHans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, et al.
Annals of Clinical and Translational Neurology|October 7, 2014
Molecular mechanism underlying the impact of vitamin D on disease activity of MSKassandra L Munger, Karl Köchert, Kelly C Simon, et al.
JAMA Neurology|October 13, 2015
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1bKathryn C Fitzgerald, Kassandra L Munger, Karl Köchert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 12, 2013
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndromeGijsbert J A Nagtegaal, Christoph Pohl, Mike P Wattjes, et al.
Pageof 7